Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex

NEW YORK, October 2, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Actavis plc (NYSE: ACT), Bristol-Myers Squibb Company (NYSE: BMY), UnitedHealth Group Incorporated (NYSE: UNH) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6949-100free.

--
Celgene Corporation Research Reports
On September 23, 2014, Celgene Corporation (Celgene) announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. OTEZLA, which was earlier approved for the treatment of patients with active psoriatic arthritis, has now become the first inhibitor approved for the treatment of plaque psoriasis, which affects more than 125 million people worldwide. Celgene said that the latest approval was based primarily on safety and efficacy results from two multi-center, randomized, double-blind, placebo-controlled studies - ESTEEM 1 and ESTEEM 2 - conducted in adult patients with moderate to severe plaque psoriasis. The stock rose 3.32% in the next trading session to end at $96.21, but gave up gains in the subsequent sessions. The full research reports on Celgene are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/CELG/report.pdf

--
Actavis plc Research Reports
On September 25, 2014, Actavis plc (Actavis) confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market the generic version of Purdue Pharma's Butrans. The confirmation came a day after Purdue Pharma L.P. filed suit against Actavis in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. Patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner. The full research reports on Actavis are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/ACT/report.pdf

--
Bristol-Myers Squibb Company Research Reports
On September 29, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced positive results from its Phase III study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab). Based on a planned interim analysis of the co-primary endpoint, the objective response rate (ORR) was 32% in the Opdivo arm and 11% in the ICC reference arm in patients with at least six months of follow up. These data were highlighted at ESMO 2014 Congress press briefing in Madrid. In a separate press release issued on the same day, Bristol-Myers Squibb announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) - the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type. The full research reports on Bristol-Myers Squibb are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/BMY/report.pdf

--
UnitedHealth Group Incorporated Research Reports
On September 29, 2014, UnitedHealth Group Inc. (UnitedHealth) informed that around 75 employees of the Company teamed up with Tampa Bay Buccaneers players and staff to distribute "Learning Gardens" to seven Title 1 grade schools in Tampa. Learning Gardens are produce gardens that enable students to help plant and nurture a garden, and learn about and sample new fruits and vegetables. The Company informed that these Learning Gardens will be planted at LaVoy Exceptional Center, Sulphur Springs, Foster, Sheehy, Edison, Potter and Graham elementary schools. "UnitedHealthcare and our employees are grateful for the opportunity to partner with the Buccaneers to help Florida schoolchildren learn more about healthy foods, and improve their health and well-being," said T. David Lewis, CEO, UnitedHealthcare of Central North Florida. The full research reports on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/UNH/report.pdf

--
Vertex Pharmaceuticals Incorporated Research Reports
On September 29, 2014, the stock of Vertex Pharmaceuticals Inc. (Vertex) hit a fresh 52-week high and ended the trading session higher by 0.26% at $113.90. Shares in Vertex opened the session at $112.99, and fluctuated in the range of $110.91 - $116.88, with a total of 2.07 million shares changing hands. Also, the stock remained well above its 50-day and 200-day moving averages of $94.36 and $80.72, respectively. Moreover, the Company's shares have rallied 21.73% in the last one month, significantly outperforming the NASDAQ 100 index which fell 1.62% during the same period. The full research reports on Vertex are available to download free of charge at:

http://www.analystsreview.com/Oct-02-2014/VRTX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review